Why Global Pharma Loves Japan
11:30 am – 1 pm
Read the Event Summary.
Henry McKinnell, Chairman & CEO, Pfizer Inc
Michael Sovern, Chairman, Japan Society
Pfizer’s recent merger with Pharmacia has created the number one prescription drug-seller in Japan. Rapid changes, in the industry and in society, are making Japan an exciting growth opportunity for the pharma sector as demand increases. Deregulation means testing and drug trials have been streamlined, and patients are insisting on more information about their treatment. While Japanese pharmaceutical companies have strong R&D, they are seeking strategic marketing opportunities in the West to boost thin profits at home. Henry McKinnell, Chairman & CEO of Pfizer Inc, explains why Japan is such an important market, and explores business opportunities presented by its new openness in the context of the pharmaceutical industry’s global integration.
11:30 am Registration & reception
12 – 1 pm Program
Tickets: Corporate members are entitled to a designated number of free admissions to this event, based on their company’s current membership level. These reservations must be made at least 48 hours prior to the event. Additional corporate registrations pay the discounted corporate member rate of $10, nonmember admission is $15.
Refunds will not be issued after noon, two business days before the program, but substitutes are welcome. No shows will be billed.
- Monday, May 19, 2003
- 11:30 am